Description: BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Home Page: www.beigene.com
BGNE Technical Analysis
55 Cambridge Parkway
Cambridge,
MA
02142
United States
Phone:
781-801-1800
Officers
| Name | Title |
|---|---|
| Mr. John V. Oyler | Co-Founder, Exec. Chairman & CEO |
| Dr. Xiaobin Wu Ph.D. | Pres, COO & GM of China |
| Dr. Xiaodong Wang Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director |
| Ms. Julia Wang | CFO & Principal Accounting Officer |
| Mr. Wang Lai | Global Head of R&D |
| Mr. Daniel Maller | VP of Fin. & Accounting |
| Ms. Mi Zhou | Sr. Director of Investor Relations |
| Mr. Kevin C. Mannix | Sr. VP of Investor Relations. |
| Ms. Diana Lee Francis | VP and Global Head of Quality & Regulatory Compliance |
| Mr. Chan Lee | Gen. Counsel |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.6683 |
| Price-to-Sales TTM: | 16.8003 |
| IPO Date: | 2016-02-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 9000 |